Market Place
Sourcing Support
HUTCHMED To Present Clinical Data At ESMO And World Lung Cancer Conf
08 Sep 2024 //
GLOBENEWSWIRE
Hutchmed in collab with Hengrui initiate phase II/III trial of surufatinib
16 May 2024 //
PHARMABIZ
HUTCHMED, Hengrui Phase 2/3 Pancreatic Cancer Trial Begins
13 May 2024 //
GLOBENEWSWIRE
HUTCHMED Announces Continued Inclusion of ELUNATE and SULANDA
12 Dec 2023 //
GLOBENEWSWIRE
FDA rejects two China-developed cancer drugs
03 May 2022 //
BIOPHARMADIVE
Hutchmed announces agreement with NHSA for adding oncology drugs Elunat
06 Dec 2021 //
PHARMABIZ
HUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA & TUOYI
20 Sep 2021 //
GLOBENEWSWIRE
USFDA Accepts Filing of HUTCHMED’s NDA for Surufatinib
01 Jul 2021 //
GLOBENEWSWIRE
HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda in China)
18 Jun 2021 //
GLOBENEWSWIRE
China NMPA approves Chi-Med’s surufatinib
01 Jan 2021 //
PHARMABIZ
Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China)
30 Dec 2020 //
PRESS RELEASE
Rolling Submission for Surufatinib Started for Advanced Neuroendocrine Tumors
28 Dec 2020 //
ONCLIVE
Rolling Submission for Surufatinib Started for Advanced Neuroendocrine Tumors
28 Dec 2020 //
ONCLIVE
With plans to bring surufatinib stateside, Chi-Med vastly scales up MFG
09 Dec 2020 //
ENDPTS
Surufatinib Is A Potential New Option In Advanced Pancreatic Nets
21 Sep 2020 //
ESMO
Chi-Med Highlights Surufatinib PhIII Results At ESMO & The Lancet
21 Sep 2020 //
GLOBENEWSWIRE
Nearly 30 COVID vaccine candidates are under development, says health ministry
19 Sep 2020 //
PHARMABIZ
Chi-Med Highlights Clinical Data to be Presented at the Upcoming ESMO
24 Aug 2020 //
PRESS RELEASE
Chi-Med Plans to Submit Marketing Authorization Application for Surufatinib
10 Aug 2020 //
PRESS RELEASE
Innovent Announces First Patient Dosed in a Ph 1b Clinical Trial of Sintilimab
08 Jul 2020 //
PRNEWSWIRE
Chi-Med Highlights Clinical Data to be Presented at the Upcoming ASCO20
14 May 2020 //
PRESS RELEASE
Chi-Med Highlights Presentations of Surufatinib at the Upcoming AACR
22 Apr 2020 //
GLOBENEWSWIRE
Chi-Med`s surufatinib bags US fast track designations
16 Apr 2020 //
PHARMATIMES
Hutchison MediPharma begins sulfatinib Phase I trial in US
05 Nov 2015 //
NEWS MEDICAL
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.